

**Conflict of Interest  
All Trials NOT Permanently Closed (as of February 2, 2017)**

<b>TRIAL</b>	<b>NAME</b>	<b>TRIAL STATUS</b>	<b>TRIAL TYPE</b>	<b>NCI US-Affiliated (Yes or No)</b>	<b>Company/ Commercial entity</b>
<b>BRAIN</b>					
CE2	Phase III Intergroup Randomized Comparison of Radiation Alone versus Pre-radiation Chemotherapy For Pure and Mixed Anaplastic Oligodendrogliomas.	Closed	IG Led	Yes	No commercial entity
CE5	Primary Chemotherapy with Temozolomide vs. Radiotherapy in Patients With Low Grade Gliomas After Stratification for Genetic 1p Loss: A Phase III Study.	Closed	IG Led	No	Merck, Schering
CEC1	Phase III Trial On Concurrent And Adjuvant Temozolomide Chemotherapy In Non-1p/19q Deleted Anaplastic Glioma. The CATNON Intergroup Trial.	Closed	IG Led	Yes	Merck, Schering
CEC2	Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma	Closed	IG Led	Yes	Merck, Schering
CEC3	A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease	Closed	IG Led	Yes	No commercial entity
CEC5	Phase II Study of Corticosteroid + Bevacizumab vs Corticosteroid + Placebo (BeST) for Radionecrosis after Radiosurgery for Brain Metastases	Open	IG Led	Yes	Hoffman-La Roche/Genentech
CEC6	Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma	Open	IG Led	Yes	Merck, Schering
<b>BREAST</b>					
MA17	A Phase III Randomized Double Blind Study of Letrozole versus Placebo in Women with Primary Breast Cancer Completing Five or More Years of Adjuvant Tamoxifen	Closed	CTG Led	Yes	Novartis
MA17R	A Double Blind Randomization to Letrozole or Placebo for Women Previously Diagnosed with Primary Breast Cancer Completing Five Years of Adjuvant Aromatase Inhibitor Either as Initial Therapy or After Tamoxifen (Including Those in the MA.17 Study)	Closed	CTG Led	Yes	Novartis
MA20	A Phase III Study of Regional Radiation Therapy in Early Breast Cancer	Closed	CTG Led	No	No commercial entity
MA24	A Randomized Three-Arm Multi-Centre Comparison of 1 Year and 2 Years of Herceptin versus no Herceptin in Women With HER2-positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy	Closed	IG Led	No	Hoffmann-La Roche Limited
MA26	Phase III Trial of Observation +/- Tamoxifen Vs. Rt +/- Tamoxifen For Good Risk Duct Carcinoma In-Situ (DCIS) of The Female Breast	Closed	IG Led	Yes	No commercial entity
MA28	Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment For Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer	Closed	IG Led	Yes	Genentech (with NCI)
MA31	A Randomized, Open-Label, Phase III Study of Taxane Based Chemotherapy with Lapatinib or Trastuzumab as First-Line Therapy for Women with HER2/neu Positive Metastatic Breast Cancer	Closed	CTG Led	No	GlaxoSmithKline
MA32	A Phase III Randomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer	Closed	CTG Led	Yes	Apotex Inc.
MA33	A Randomised Phase III Study Of Radiation Doses And Fractionation Schedules For Ductal Carcinoma In Situ (DCIS) Of The Breast	Closed	IG Led	No	No commercial entity
MA34	A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients with Operable HER2-Positive Primary Breast Cancer	Closed	IG Led	No	Hoffmann-La Roche Limited

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
MA36	A Randomised, Double-Blind, Parallel group, Placebo-Controlled Multicenter Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy	Open	IG Led	No	AstraZeneca
MA37	PALLAS: PALbociclib Collaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib with Adjuvant Endocrine Therapy versus Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer	Open	IG Led	No	Pfizer
MA38	Randomized Phase II Study Comparing Two Different Schedules of Palbociclib plus Second Line Endocrine Therapy in Women with Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer	Open	CTG Led	No	Pfizer
MA39	Tailor RT: A Randomized Trial of Regional Radiotherapy in Node Positive Luminal A Breast Cancer	Planned	CCTG-Led		No commercial entity
MAC1	A Randomized Trial of Adjuvant Chemotherapy With Standard Regimens, Cyclophosphamide, Methotrexate and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide - (AC), Versus Capecitabine in Women 65 Years and Older With Node Positive or Node-Negative Breast Cancer	Closed	IG Led	Yes	Hoffmann-La Roche/Genentech (capecitabine)
MAC4	A Phase III Trial Evaluating the Role of Ovarian Function Suppression and the Role of Exemestane as Adjuvant Therapies for Premenopausal Women With Endocrine Responsive Breast Cancer	Closed	IG Led	Yes	Pfizer (exemestane)
MAC5	A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer	Closed	IG Led	Yes	Pfizer (exemestane)
MAC7	Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First Line Therapy for Post Menopausal Women With Metastatic Breast Cancer	Closed	IG Led	Yes	Astrazeneca
MAC8	A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast Cancer.	Closed	IG Led	Yes	No commercial entity (investigator choice of chemo)
MAC9	Prognostic Factor Panel to Predict Preferred Therapy for Node-Positive Postmenopausal Breast Cancer Patients	Closed	IG Led	Yes	Bayer Schering Pharma (Clodronate), Roche (ibandronate), Novartis (zoledronic acid)
MAC11	A Phase III Trial of Continuous Schedule AC + G vs Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node-Negative Breast Cancer.	Closed	IG Led	Yes	AMGEN (darbepoetin filgastrim, peg filagastim);
MAC12	Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial	Closed	IG Led	Yes	Genomic Health
MAC13	Adjuvant, Lapatinib and/or Trastuzumab Treatment Optimisation Study A Randomised, Multi-Centre, Open-Label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, Their Sequence and Their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer	Closed	IG Led	Yes	GlaxoSmithKline; Roche/Genentech
MAC14	A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer	Closed	IG Led	Yes	No commercial entity
MAC15	A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy Plus or Minus Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx For Positive Node, Endocrine Responsive Breast Cancer.	Closed	IG Led	Yes	Genomic Health

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
MAC18	POSITIVE: A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer who Desire Pregnancy	Open	IG Led	Yes	No commercial entity
MAC19	A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1 -3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy	Open	IG Led	Yes	No commercial entity
MAC20	Randomized Phase III Trial Evaluating the Role of Weight Loss In Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer	Open	IG Led	Yes	Nestle
MAC21	Aspirin for Breast Cancer (ABC): Randomized Trial of Aspirin as Adjuvant Therapy for Node Positive Breast Cancer	Planned	IG Led	Yes	Bayer
MAP3	A Phase III Randomized Study of Exemestane Versus Placebo in Postmenopausal Women at Increased Risk of Developing Breast Cancer	Closed	CTG Led	Yes	Pfizer Inc.
MAX1	Long term Anastrozole vs Tamoxifen Treatment Effects (LATTE)	Open	IG Led	No	No commercial entity
<b>GASTROINTESTINAL</b>					
CO21	A Phase III Study of the Impact of a Physical Activity Program on Disease-Free Survival in Patients with High Risk Stage II or Stage III Colon Cancer: A Randomized Controlled Trial (CHALLENGE).	Open	CTG Led	No	No commercial entity
CO25	Focus 4: Molecularly Stratified RCT Programme for Selection of Therapy in Metastatic CRC Post Induction 1st Line Treatment	Planned	IG Led	No	Bayer
CO26	A Phase II/III Trial of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies	Open	CTG Led	No	AstraZeneca
CO27	Irinotecan and Oxaliplatin for Colon cancer in the Adjuvant Setting: mFOLFIRINOX triplet chemotherapy for high-risk stage III colon cancer in adjuvant setting (IROCAS study): A Phase III Randomised Trial	Planned	IG Led	No	No commercial entity
CO28	Neoadjuvant chemotherapy and Transanal Excisional MicroSurgery in Early Rectal Cancer- The NeoTEMs Study	Planned	CCTG-Led	No	No commercial entity
CRC3	A Randomized Phase III Study Comparing 5-FU, Leucovorin and Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in Patients With Stage II Colon Cancer at High Risk for Recurrence to Determine Prospectively the Prognostic Value of Molecular Markers	Closed	IG Led	Yes	Sanofi-Aventis; Hoffmann-La Roche/Genentech
CRC4	Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-Operative Chemoradiation	Closed	IG Led	Yes	Sanofi-Aventis; Hoffmann-La Roche/Genentech
CRC5	A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum	Closed	IG Led	Yes	Hoffmann-La Roche/Genentech, BristolMyersSquibb, Imclone;
CRC6	A Phase III Trial of 6 versus 12 Treatments of Adjuvant Folfox Plus Celecoxib or Placebo For Patients With Resected Stage III Colon Cancer	Closed	IG Led	Yes	Sanofi-Aventis; Pfizer
CRC7	A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision (PROSPECT)	Open	IG Led	Yes	No commercial entity
ES2	A Randomized Phase III Study in Advanced Oesophageal Cancer To Compare Quality of Life and Palliation of Dysphagia In Patients Treated With Radiotherapy Versus Chemo-Radiotherapy.	Closed	IG Led	No	No commercial entity
GA1	A Randomized Phase II/III Trial of Preoperative Chemoradiotherapy versus Preoperative Chemotherapy For Resectable Gastric Cancer (TOPGEAR)	Open	IG Led	No	Novartis

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
GA3	A Randomised Phase III Double-Blind Placebo-Controlled Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC)	Open	IG Led	No	Bayer Healthcare Pharmaceuticals
HE1	Phase III Study of Palliative Radiotherapy for Symptomatic Hepatocellular Carcinoma and Liver Metastases	Open	CTG Led	No	No commercial entity
HEC1	Phase III Randomized Study of Sorafenib Plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)	Closed	IG Led	Yes	Bayer
NEC2	Randomized Phase II Study of Everolimus Alone versus Everolimus Plus Bevacizumab in Patients with Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours	Closed	IG Led	Yes	Novartis (via NCI), Genentech
NEC3	Prospective Randomized Phase II Trial of Pazopanib (NSC# 737754, IND 75648) Versus Placebo in Patients with Progressive Carcinoid Tumors	Closed	IG Led	Yes	Novartis
PA6	Multicentre Randomized Phase III Trial Comparing 6-Month Adjuvant Chemotherapy With Gemcitabine Versus 5-fluorouracil, Leucovorin, Irinotecan and Oxaliplatin (mFolfirinox) In Patients With Resected Pancreatic Adenocarcinoma	Closed	IG Led	No	Sanofi-Aventis Inc.
PA7	A Randomized Phase II/III Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel and Durvalumab or Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st line therapy in Metastatic Pancreatic Adenocarcinoma	Open	CTG Led	No	AstraZeneca
<b>GENITOURINARY</b>					
BL12	A Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen	Open	CTG Led	No	Celgene Inc.
BLC1	A Phase III Surgical Trial to Evaluate the Benefit of a Standard versus an Extended Pelvic Lymphadenectomy Performed at the Time Of Radical Cystectomy For Muscle Invasive Urothelial Cancer	Open	IG Led	Yes	No commercial entity
BLC2	Phase III randomized Adjuvant study of pembrolizumAb in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR ) versus placebo	Planned	IG Led	Yes	Merck
BLC3	A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-naive High-grade Non-muscle Invasive Bladder Cancer	Planned	IG Led	Yes	JBL
BLC4	Phase II Trial of Atezolizumab in BCG-Unresponsive Non-muscle Invasive Bladder Cancer	Planned	IG Led	Yes	Genentech
PR13	RADICALS: Radiotherapy and Androgen Deprivation In Combination After Local Surgery	Closed	IG Led	No	Sanofi; AstraZeneca; Schering; Abbvie; Aventis;
PR15	Randomized Phase II Feasibility Trial Of Image Guided External Beam Radiotherapy With Or Without High Dose Rate Brachytherapy Boost In Men With Intermediate-Risk Prostate Cancer	Closed	CTG Led	No	No commercial entity
PR17	Randomised Phase III Trial of Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer: ENZAMET	Open	IG Led	No	ASTELLAS
PR19	A Randomized Phase II Trial Evaluating High Dose Rate Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer	Open	CCTG-Led	No	No commercial entity
PRC3	A Randomized Phase III Study of Neo-Adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy Versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer	Closed	IG Led	Yes	Sanofi-Aventis
PRC4	Phase III Trial of Enzalutamide (NSC#766085) Versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer	Closed	IG Led	Yes	ASTELLAS; Janssen
REC2	ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma	Closed	IG Led	Yes	Pfizer, Bayer

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
REC3	A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal	Open	IG Led	Yes	Pfizer, Exelixis, AstraZeneca
<b>GYNECOLOGY</b>					
CX5	A Randomized Phase III Trial Comparing Radical Hysterectomy and Pelvic Node Dissection vs Simple Hysterectomy and Pelvic Node Dissection in Patients with Low-Risk Early Stage Cervical Cancer. (SHAPE)	Open	CTG Led	No	No commercial entity
EN7	Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma.	Closed	IG Led	No	No commercial entity
OV18	A Randomized Trial of Concurrent Cediranib [AZD2171] (with Platinum-Based Chemotherapy) and Maintenance Cediranib in Women with Platinum-Sensitive Relapsed Ovarian Cancer.	Closed	IG Led	No	AstraZeneca; Medical Research Council; University College London
OV24	STICs and STONES: Prospective Assessment of Aspirin in Chemoprevention of High-Risk Ovarian Cancer: A Randomized Translational Window of Opportunity Trial	Planned	CTG Led	No	Bayer
OVC1	A Phase III Study Comparing Single-agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-based Chemotherapy in Women with Recurrent Platinum-sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Open	IG Led	Yes	AstraZeneca
OVC2	A Randomized Phase II/III study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)	Open	IG Led	Yes	AstraZeneca
<b>HEAD AND NECK</b>					
HN6	A Phase III Study Of Standard Fractionation Radiotherapy With Concurrent High-Dose Cisplatin Versus Accelerated Fractionation Radiotherapy With Panitumumab In Patients With Locally Advanced Stage III And IV Squamous Cell Carcinoma Of The Head And Neck.	Closed	CTG Led	No	Amgen
HN9	Randomized Phase II Study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC)	Planned	CCTG-Led	No	AstraZeneca
<b>HEMATOLOGY</b>					
AL5	Dana Farber Cancer Institute (DFCI) Acute Lymphoblastic Leukemia (ALL) Adult Consortium Trial: Adult ALL Trial	Closed	IG Led	Yes	Sigma Tau (Baxter), Novartis
ALC2	A Phase III Randomized, Double-Blind Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy + Midostaurin (PK412) (IND # 101261) or Placebo in Newly Diagnosed Patients < 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia (AML).	Closed	IG Led	Yes	Novartis
ALC3	A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)	Closed	IG Led	Yes	Merck
ALC4	A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults.	Planned	IG Led	Yes	Amgen
CL3	A Genetic, Risk-Stratified Randomized Phase II Study of Four Fludarabine/Antibody Combinations For Patients with Symptomatic Previously Untreated Chronic Lymphocytic Leukemia	Closed	IG Led	Yes	Celgene Corporation

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
CLC2	A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (> = to 65 years of age) with Chronic Lymphocytic Leukemia (CLL).	Closed	IG Led	Yes	Lundbeck Canada Inc. Teva Oncology
CLC2E	A Prospective Economic Analysis of NCIC CTG CLC.2/ALLIANCE A041202: A Randomized Phase III CLL Study of Bendamustine Plus Rituximab versus Ibrutinib Plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (>= 65 Years of Age) With Chronic Lymphocytic Leukemia	Closed	CTG Led	No	Janssen Inc.
HD8	BEACOPP (4 cycles escalated + 4 cycles baseline) versus ABVD (8 cycles) in stage III & IV Hodgkin's lymphoma	Closed	IG Led	No	No commercial entity
HD9	An Adaptive Design Phase II-III Trial of Brentuximab Vedotin-based therapy or GDP Salvage Chemotherapy Followed by High dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma	Planned	CCTG-Led	No	Takeda
LY7	Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) in Remission Induction and Maintenance Treatment of Relapsed Follicular Non-Hodgkins Lymphoma: A Phase III Randomized Clinical Trial	Closed	IG Led	No	Hoffmann-La Roche Limited
LY12	A Phase III Study of Gemcitabine, Dexamethasone, and Cisplatin Compared to Dexamethasone, Cytarabine, and Cisplatin Plus/Minus Rituximab [(R) -GDP VS (R) -DHAP] as Salvage Chemotherapy for Patients with Relapsed or Refractory Aggressive Histology Non-Hodgkin's Lymphoma Prior to Autologous Stem Cell Transplant and Followed by Maintenance Rituximab Versus Observation.	Closed	CTG Led	No	Eli Lilly, Roche
LY15	A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma.	Closed	CTG Led	No	Celgene Inc.
LY16	A Phase III Open-Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma	Closed	IG Led	No	Celgene
LY17	A Multi-stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma	Open	CTG Led	No	Janssen Inc.
LYC1	Intergroup Randomized Phase II Four Arm Study In Patients With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab+ Bendamustine Followed By Rituximab Consolidation (RB -> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed By Rituximab Consolidation (RBV -> R), Arm C = Rituximab + Bendamustine Followed By Lenalidomide + Rituximab Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)	Closed	IG Led	Yes	Lundbeck Canada Inc. Teva Oncology
MDC1	A Randomized Phase II/III Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)	Closed	IG Led	Yes	Merck, Celgene
MYX1	A Single Arm Phase II Study of High-Dose Weekly Carfilzomib plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma 1-3 Prior Therapies	Open	IG Led	No	Onyx; MCRN (Myeloma Canada)
<b>INVESTIGATIONAL NEW DRUG</b>					
I206	A Phase II Study of Sunitinib or Temozolomide in Patients with Advanced Rare Tumours.	Closed	CTG Led	No	Pfizer Canada Inc.
I208	Phase I/II Study of the P13Kinase Inhibitor BKM120 Given in Combination with Panitumumab in Patients with Metastatic or Advanced RAS-Wild Type Colorectal Cancer.	Closed	CTG Led	No	Novartis

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
I210	A Randomized Phase II Study of Reolysin in Combination with FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Patients with Metastatic Colorectal Cancer.	Closed	CTG Led	No	Oncolytics Biotech
I211	A Randomized Phase II Study of Reolysin in Patients With Previously Treated Advanced or Metastatic, Non Small Cell Lung Cancer Receiving Standard Salvage Therapy.	Closed	CTG Led	No	Oncolytics Biotech
I213	A Randomized Phase II Study of Reolysin For Patients Receiving Standard Weekly Paclitaxel Therapy as Therapy For Advanced/Metastatic Breast Cancer	Closed	CTG Led	No	Oncolytics Biotech
I214	A Phase I/II Study of MG1 Maraba/MAGE-A3 (MG1MA3), With and Without Adenovirus Vaccine, With Transgenic MAGE-A3 Insertion (AdMA3) in Patients with Incurable Advanced/Metastatic MAGE-A3-Expressing Solid Tumours	Hold	CTG Led	No	OHRI, Turnstone
I215	A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC Who are Receiving Standard Chemotherapy Regimens.	Closed	CTG Led	No	AstraZeneca
I216	Phase II Study of Buparlisib in Patients with Relapsed and Refractory Chronic Lymphocytic Leukemia	Closed	CTG Led	No	Novartis Pharmaceuticals Canada Inc.
I217	A Phase I and Enrichment Study of Low-Dose Metronomic Topotecan and Pazopanib in Pediatric Patients with Recurrent or Refractory Solid Tumours Including CNS Tumours.	Hold	IG Led	No	Novartis
I218	A Study of Vinblastine and Temozolomide in Pediatric Patients with Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours	Hold	CTG Led	No	Pfizer Canada Inc.
I219	A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Cisplatin Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer	Hold	CTG Led	No	AstraZeneca Canada Inc.
I221	A Dose-Ranging Study of IPH2201 in Patients with High Grade Serous Carcinoma of Ovarian, Fallopian Tube or Peritoneal Origin	Open	CTG Led	No	Innate Pharma; OptumInsight Canada Inc.
I222	A Phase I/II Study of the mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Patients with Previously Treated Glioblastoma Multiforme	Open	CTG Led	No	AstraZeneca
I223	A Phase II Study of Ribociclib, A CDK4/6 Inhibitor, in Patients with Metastatic Castration-Resistant Prostate Cancer	Planned	CTG Led	No	Novartis
I224	A Phase II Study of Concurrent Dabrafenib and Trametinib with Stereotactic Radiation in the Management of Patients with BRAF Mutation-Positive Malignant Melanoma and Brain Metastases	Open	CCTG-Led	No	Novartis
I225	A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker	Open	CCTG-Led	No	Merck
I226	A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given with or without Standard Chemotherapy Regimens	Open	CCTG-Led	No	AstraZeneca
I227	A Phase II Randomized Study of Pembrolizumab Alone or in Combination with Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma	Open	CTG Led	No	Merck
I228	A Phase II Study of Durvalumab and Tremelimumab in Patients with Advanced Rare Tumours	Open	CCTG-Led	No	AstraZeneca
I229	A Phase 1b Pharmacodynamic Study of Durvalumab (MEDI4736) in Patients with HER-2 Positive Metastatic Breast Cancer (MBC) Receiving Trastuzumab	On Hold	CCTG-Led	No	AstraZeneca
I230	A Phase II Trial of Durvalumab and Tremelimumab in Pretreated, Metastatic or Locally Refractory Estrogen Receptor Positive, HER2 negative Breast Cancer	Planned	CCTG-Led	No	AstraZeneca
I231	A Phase I/II Study of CX5461	On Hold	CCTG-Led	No	Senhwa Biosciences

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
I232	A Phase II Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Metastatic Castration Resistant Prostate Cancer	Open	CCTG-Led	No	AstraZeneca
I234	Prostate Cancer Biomarker Enrichment and Treatment Selection (PC_BETS) Study - Master Screening Protocol	Planned	CCTG-Led	No	AstraZeneca, Bayer
<b>LUNG</b>					
BR16	Phase III Chemoprevention Trial of Selenium Supplementation in Persons With Resected Stage 1 Non-Small Cell Lung Cancer	Closed	IG Led	Yes	Cypress Systems
BR28	Concurrent ONce-daily VErSUS twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status	Closed	IG Led	No	No commercial entity
BR31	A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer	Open	CTG Led	No	AstraZeneca, MedImmune
BR34	A Randomized Trial of Durvalumab (MEDI4736) and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)	Planned	CCTG-Led	No	AstraZeneca
BRC2	A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)	Closed	IG Led	Yes	Roche/Genentech
BRC2E	A Prospective Economic Analysis of NCIC CTG BRC.2/E1505 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>= 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)	Closed	CTG Led	No	Roche/Genentech
BRC5	A Phase III Randomized Trial of Lobectomy Versus Sublobular Resection For Small, (</= to 2cm) Peripheral Non-Small Cell Lung Cancer	Open	IG Led	Yes	No commercial entity
BRC6	Phase II/III Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer.	Open	IG Led	Yes	MedImmune (Astra Zeneca), Genentech, Pfizer, Astra Zeneca, BMS
<b>MELANOMA</b>					
ME10	Phase III Randomized Study of Four Weeks High Dose IFN-a2b in Stage T2b N0, T3a-bN0, T4a-b N0, and T1-4, N1a, 2a (microscopic) Melanoma	Closed	IG Led	Yes	Merck
ME13	A Randomized Phase III Trial of the Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP)	Open	CCTG-Led	No	No commercial entity
MEC3	A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon a-2b for Resected High-Risk Melanoma	Closed	IG Led	Yes	BristolMyersSquibb
MEC4	Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma	Closed	IG Led	Yes	Exelixis
MEC5	A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma	Open	IG Led	Yes	Merck
<b>SARCOMA</b>					
SR4	Phase III Randomized, Intergroup Trial Assessing the Clinical Activity of STI-571 at Two Dose Levels in Patients with Unresectable or Metastatic Gastrointestinal Stromal Tumors (GIST) Expressing the KIT Receptor Tyrosine Kinase (CD117)	Closed	IG Led	Yes	Novartis
SRC1	A Phase III Randomized Double-Blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following the Resection of Primary Gastrointestinal Stromal Tumors (GIST)	Closed	IG Led	Yes	Novartis
SRC6	Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib	Open	IG Led	Yes	Novartis

TRIAL	NAME	TRIAL STATUS	TRIAL TYPE	NCI US-Affiliated (Yes or No)	Company/ Commercial entity
SRC7	A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)	Closed	IG Led	Yes	Bayer
<b>SYMPTOM CONTROL</b>					
SC24	A Phase II Randomized Feasibility Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases	Open	CTG Led	No	No commercial entity
<b>PRECISION MEDICINE</b>					
PM1	Canadian Profiling and Targeted agent Utilization tRial (CAPTUR)	Planned	CCTG-Led	No	Boehringer-Ingelheim, BMS, Roche, Merck, Pfizer, AstraZeneca